Theranexus SA (FR:ALTHX) has released an update.
Theranexus reports a slight increase in cash reserves to €1.9 million as of September 30, 2024, aided by a significant research tax credit. The company remains focused on advancing its treatments for rare neurological diseases, aiming to register its liquid miglustat formulation in Europe and initiate a phase 3 trial for Batten disease.
For further insights into FR:ALTHX stock, check out TipRanks’ Stock Analysis page.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
